March 17, 2025 — Koru Pharma, a global leader in medical aesthetics, has secured a patent for its next-generation hyaluronic acid-agarose filler technology, a breakthrough attracting significant industry attention. Recognised by Asia Economy as a major advancement in dermal fillers, this innovation eliminates chemical cross-linkers, setting a new standard for safety and efficacy.

Revolutionising the Filler Industry

In a feature by Asia Economy, Koru Pharma’s newly patented semi-interpenetrating polymer network (Semi-IPN) technology is hailed as a transformative development. By integrating hyaluronic acid (HA) and agarose, this formulation offers a safer alternative to BDDE-crosslinked fillers, which have long been associated with safety concerns. With precise control over viscoelastic properties, it enhances biocompatibility, longevity, and performance, addressing the growing demand for natural, reliable aesthetic solutions.

Redefining Safety and Performance

By eliminating chemical cross-linkers, Koru Pharma’s hyaluronic acid-agarose innovation directly responds to the increasing demand for high-performance, low-risk dermal fillers. This technology surpasses traditional cross-linked fillers by improving biocompatibility, stability, and injection precision, redefining standards in medical aesthetics. Koru Pharma remains committed to safety and efficacy, offering innovative solutions for professionals and patients alike.

A Legacy of Excellence and Innovation

This patent strengthens Koru Pharma’s legacy of innovation, following its hyaluronic acid-chitosan patent last year and the launch of the Koru-Peptide range in early 2025. An official representative from Koru Pharma stated: "We are dedicated to advancing the next-generation filler technology to meet evolving market demands. Our focus remains on strengthening market-driven technological development to further solidify our position as a global leader in the medical aesthetics industry."

Since its founding in 2016, Koru Pharma has expanded its operations to over 120 countries, supplying premium-quality fillers, skin boosters, and aesthetic medical products, solidifying its global presence.

Shaping the Future of K-Beauty

By commercialising this BDDE-free technology, Koru Pharma is poised to elevate K-Beauty’s standing worldwide. As the aesthetics sector shifts towards safer, cutting-edge solutions, this patent reaffirms the company’s role as a trailblazer in medical aesthetics.

Source: Asia Economy (March 17, 2025). “코루파마, 히알루론산-아가로즈 활용한 차세대 필러 기술특허 등록”